West Bend, Wisc.-based Spaulding Clinical Research is partnering with clinicalRSVP (clinical Research Subject Verification Program), a provider of participant registry services in North America.
Spaulding Clinical is joining participating clinical sites that utilize clinicalRSVP to check participant eligibility requirements before dosing commences. Spaulding Clinical is the first site in the Midwest to join clinicalRSVP’s network, which includes sites on both coasts.
Spaulding Clinical said it chose clinicalRSVP as its preferred provider of dual enrollment protection services because of its expansive network, proven track record, ease of operational implementation and regulatory compliance. clinicalRSVP has developed a network of sites that currently includes more than 25% of all phase I beds in North America.
“Dual enrollment is becoming an incredibly hot topic in the clinical pharmacology circuit as sponsors are becoming very keen to ensure subjects are only in their studies,” said Daniel Selness, general manager and senior vice president of operations at Spaulding Clinical. “Spaulding is pleased to be able to provide this added measure of diligence for our study sponsors.”
“The addition of Spaulding Clinical represents a terrific advancement for clinicalRSVP and for those who sponsor and conduct phase I clinical trials across North America,” said Darran Boyer, president of clinicalRSVP. “We are pleased that our network now spans from coast to coast, including the Midwest and into Canada.”
clinicalRSVP is a North American network that prevents research volunteers from enrolling in multiple research studies concurrently. This blinded cooperative registry allows investigators to confidentially and securely verify patient eligibility requirements prior to patient enrollment in clinical trials, resulting in advances to clinical research data integrity and participant safety.
Spaulding Clinical Research provides clinical pharmacology and cardiac core lab clinical research services, and is a medical device manufacturer. It operates a 105-bed clinical pharmacology unit with 96 beds of telemetry. As a phase I-IV core ECG laboratory provider, Spaulding Clinical offers equipment provisioning and electrocardiograph over-reading services.
